In yesterday’s Wall Street session, Chimerix Inc. (NASDAQ:CMRX) shares traded at $1.72, down -6.52% from the previous session.
As of this writing, 6 analysts cover Chimerix Inc. (NASDAQ:CMRX). The consensus rating among analysts is ‘Buy’. CMRX stock price is now -13.39% away from the 50-day moving average and -35.62% away from the 200-day moving average. The market capitalization of the company currently stands at $161.34M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 0 analysts who have given it a hold rating, whereas 5 have given it a buy rating.
With the price target of $7, CapitalOne recently initiated with Overweight rating for Chimerix Inc. (NASDAQ: CMRX). On April 29, 2021, Maxim Group recently initiated its ‘Buy’ rating on the stock quoting a target price of $20, while ‘Cowen’ rates the stock as ‘Outperform’.
In other news, MIDDLETON FRED A, Director bought 20,000 shares of the company’s stock on Sep 29. The stock was bought for $37,176 at an average price of $1.86. Upon completion of the transaction, the Director now directly owns 40,000 shares in the company, valued at $68800.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 29, Principal Accounting Officer Jakeman David sold 4,400 shares of the business’s stock. A total of $8,185 was realized by selling the stock at an average price of $1.86. This leaves the insider owning 127,532 shares of the company worth $0.22 million. Insiders disposed of 7,700 shares of company stock worth roughly $13244.0 over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CMRX stock. A new stake in Chimerix Inc. shares was purchased by TWO SIGMA ADVISERS, LP during the first quarter worth $539,000. AQR CAPITAL MANAGEMENT LLC invested $316,000 in shares of CMRX during the first quarter. In the first quarter, PEAK6 INVESTMENTS LLC acquired a new stake in Chimerix Inc. valued at approximately $233,000. JACOBS LEVY EQUITY MANAGEMENT, INC acquired a new stake in CMRX for approximately $224,000. CUBIST SYSTEMATIC STRATEGIES, LLC purchased a new stake in CMRX valued at around $191,000 in the second quarter. In total, there are 179 active investors with 62.30% ownership of the company’s stock.
Tuesday morning saw Chimerix Inc. (NASDAQ: CMRX) opened at $1.8200. During the past 12 months, Chimerix Inc. has had a low of $1.27 and a high of $7.15. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 16.40, and a quick ratio of 16.40. The fifty day moving average price for CMRX is $1.9860 and a two-hundred day moving average price translates $2.6717 for the stock.
The latest earnings results from Chimerix Inc. (NASDAQ: CMRX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.27, missing analysts’ expectations of -$0.24 by -0.03. This compares to -$0.22 EPS in the same period last year. The company reported revenue of $32.55 million for the quarter, compared to $0.11 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 30325.23 percent. For the current quarter, analysts expect CMRX to generate $219.37M in revenue.
Chimerix Inc.(CMRX) Company Profile
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company’s approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
